Notably, LCAT expression is significantly lower in breast invasive carcinoma (BRCA), cholangio carcinoma (CHOL), kidney chromophobe (KICH), LIHC, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), thyroid carcinoma (THCA), and UCEC tumor tissues; LCAT expression is significantly higher in COAD, esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), KIRC, KIRP, and stomach adenocarcinoma (STAD) tumor tissues (Figure 1C). Here, LCAT is linked to lung adenocarcinoma.